$TECH

Bio-Techne (TECH) opened a new GMP manufacturing facility in Bristol, UK, to support cell therapy development. The 10,000-square-foot facility features cleanrooms for GMP small molecule production. This expansion complements Bio-Techne's existing capabilities in the US and strengthens its global manufacturing network for cell therapy applications. The company aims to provide scalable, reproducible manufacturing processes to support therapy developers.

Bio-Techne Corp's average stock price target increased from $70.9 to $73.22 by 9 analysts, with a range of $73 to $75. This suggests a 1% upside from the Oct. 1 closing price. The consensus rating remains 'Hold' among 13 analysts.

Bio-Techne (TECH) shareholders approved a $11.3B takeover by Merck KGaA at $73/share, but rejected the executive pay package. Shares closed at $72.57. The deal, subject to remaining approvals, is expected to close in late 2026 or early 2027.

BASF proposed a takeover of Evonik, reflecting defensive consolidation in Europe's chemical sector. Other notable deals include Aquarian's bid for Brighthouse Financial with a 31.4% spread, Thoma Bravo's offer for Accelerant Holdings, and Merck's potential acquisition of Bio-Techne. Bullish's $4.2B deal for Equiniti highlights tokenization trends. Spreads vary, signaling different risk profiles.

BIO-TECHNE Corp (TECH) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Exhibit 99.1 Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany MINNEAPOLIS – September 23, 2026 – Bio-Techne Corporation (NASDAQ: TECH) (“Bio-Techne”), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne

Bio-Techne (TECH) shareholders approved a merger with Merck KGaA. The deal, expected to close by early 2027, requires regulatory approvals. Bio-Techne reported $1.2B in net sales for fiscal 2025. The transaction aims to combine life sciences operations and deliver cash value to shareholders.

Bio-Techne faces a shareholder lawsuit and demand letters challenging its proxy disclosures for the pending acquisition by Merck KGaA. The lawsuit seeks to halt the shareholder vote scheduled for September 23, 2026. Bio-Techne plans to supplement the proxy with additional disclosures on the sale process and financial advisor details, which may impact investor assessment of the deal.

BIO-TECHNE Corp (TECH) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. As previously disclosed, on June 25, 2026, Bio-Techne Corporation, a Minnesota corporation (“ Bio-Techne ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Merck KGaA, Darmstadt, Germany, a German corporation with general par

Bruker (BRKR) reported Q2 revenue of $838.5M, up 5.2% YoY but missing estimates by 1.9%. Its stock fell 7.3% post-results. Avantor (AVTR) beat expectations with $1.69B revenue, up flat YoY, and its stock rose 17.1%. Waters (WAT) saw 113% revenue growth but mixed guidance, with its stock up 10.3%. Bio-Techne (TECH) and Danaher (DHR) also reported earnings, with TECH flat and DHR up 5.7% post-results.

Bio-Techne (TECH) reported flat earnings, trading at $72.35. Avantor (AVTR) beat estimates with $1.69B revenue, up 17.4%. Bruker (BRKR) missed expectations, down 11.1%. Sotera Health (SHC) reported $321.4M revenue, up 7.2%. Thermo Fisher (TMO) beat estimates with $11.99B revenue, up 18.3%.